Quantcast

Latest Cordis Stories

2011-06-15 08:00:00

BRIDGEWATER, N.J., June 15, 2011 /PRNewswire-FirstCall/ -- Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, today announced it will no longer pursue the development of the NEVO(TM) Sirolimus-Eluting Coronary Stent in order to focus on other cardiovascular therapies where significant patient need exists. The company will also stop the manufacture of CYPHER® and CYPHER SELECT® Plus...

2011-05-16 08:00:00

PARIS, May 16, 2011 /PRNewswire/ -- Cordis announces the launch in Europe of Radial Solutions, a complete portfolio for transradial interventions. New to the portfolio is the Cordis RADIALSOURCE(TM) Transradial Access Kit. RADIALSOURCE(TM) Transradial Sheaths are designed to provide physicians with atraumatic and smooth access to the radial artery during diagnostic and interventional procedures and is a result of Cordis' long standing commitment to driving innovation. The rate of...

2011-05-16 08:00:00

PARIS, May 16, 2011 /PRNewswire/ -- - Cordis Continues its History of Innovation With Two New Products: EMPIRA(TM) and RADIALSOURCE(TM) Cordis announced it has obtained CE mark for its EMPIRA(TM) and EMPIRA(TM) NC RX PTCA* Dilatation Catheters for the treatment of coronary artery disease. The EMPIRA(TM) systems are designed to enable interventional cardiologists to open patients' narrowed coronary arteries during angioplasty and stenting procedures. The EMPIRA(TM) family of...

2011-01-28 14:59:00

MARSHALL, Texas, Jan. 28, 2011 /PRNewswire/ -- A federal jury in Marshall, Texas has returned a $482 million verdict for Dickstein Shapiro LLP client Dr. Bruce N. Saffran against defendants Johnson & Johnson and its subsidiary, Cordis Corporation, in Saffran v. Johnson & Johnson and Cordis Corp., No. 2:07-CV-451 (TJW) (E.D. Texas), before Judge T. John Ward. Significantly, the jury found that the Cypher(TM) drug-eluting cardiac stent, manufactured and distributed by Cordis Corp.,...

2010-09-30 02:58:00

WATERLOO, Belgium, September 30, 2010 /PRNewswire/ -- - SORT OUT IV Data Presented at TCT in Washington DC Shows Remarkable Clinical Safety and Efficacy Measures With Both CYPHER(R) Stent and XIENCE V(R) Stent - Only CYPHER Stent has More Than 10 years of Clinical Safety Data in 70 Studies Investigators reported results of SORT-OUT IV, comparing Cordis Corporation's CYPHER(R) Sirolimus-eluting Coronary Stent and Abbott's XIENCE V (R) Everolimus-eluting Stent in the primary...

2010-09-02 06:59:00

STOCKHOLM, September 2, 2010 /PRNewswire/ -- - Additional Analysis of 18 Month Data of the SORT OUT III Trial Provides Detail on Safety and Efficacy Outcomes in Patients With Diabetes, Acute Coronary Syndrome, or Treatment of Multiple Lesions Three new analyses of subgroups from the SORT OUT III study presented at the European Society of Cardiology (ESC) meeting in Stockholm, Sweden, provide additional detail on longer-term follow-up subgroup safety and efficacy outcomes in the...

2010-08-31 05:20:00

STOCKHOLM, August 31, 2010 /PRNewswire/ -- - The Publication of 10-Year Follow-Up Test Results on the First CYPHER(R) Sirolimus-Eluting Coronary Stent Patient Reveal the Stent's Outstanding Efficacy and Safety Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today at European Society of Cardiology in Stockholm that the results of follow-up tests undertaken ten years after the first patient was treated with...

2010-08-30 10:09:00

STOCKHOLM, August 30, 2010 /PRNewswire/ -- - The Stent for Life Initiative (SFL) Celebrates its First Year Anniversary as the ESC 2010 Congress in Stockholm, Monday August 30th InspireMD Ltd., a medical device company engaged in the development and commercialization of MGuard(TM) novel stent systems, is happy to announce that it has joined the Stent for Life Initiative as a supporting organization. The Stent for Life Initiative aims to improve the delivery and patient access to...

2010-08-17 04:27:00

DALLAS, August 17, 2010 /PRNewswire/ -- - ReportsandReports Announces it Will Carry the U.S. Market for Peripheral Vascular Devices 2010 Market Research Report in its Store. Browse the complete Report on: http://www.reportsandreports.com/market-reports/us-market-for-peripheral-vasc ular-devices-2010/ (Due to the length of these URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser's URL address field. Remove the space if one exists.)...

2010-05-27 03:28:00

PARIS, May 27, 2010 /PRNewswire/ -- - New Trial Results on ExoSeal(TM) Vascular Closure Device Support its Clinical Safety* and Efficacy Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced the launch of the ExoSeal(TM) Vascular Closure Device. ExoSeal(TM) incorporates a number of new advances in technology and simplicity of design to provide precise and secure extravascular arterial closure. Cordis...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.